These Analysts Slash Their Forecasts On Haemonetics After Q1 Results
1. HAE reported Q1 earnings of $1.10, beating estimates. 2. Quarterly sales reached $321.394 million, exceeding expectations. 3. FY2026 EPS guidance reaffirmed between $4.70 and $5.00. 4. JP Morgan downgraded HAE from Overweight to Neutral. 5. Other analysts maintained rating but lowered price targets.